US FDA And Sponsors Resolve Disclosure Issues On Complex Trial Design Pilot Projects
Executive Summary
Agency officials can now discuss the ideas that have been accepted, though not in great detail.
You may also be interested in...
RWE Program Offers Sponsors Chance At Novel Uses, But In Exchange For Disclosing Proposals
The disclosure requirement to participate includes an option for the US FDA to include the ideas on new regulatory uses for real-world evidence in a guidance or speak about them at public forums in order to ‘promote innovation.’
PDUFA VII: Human Factors Review, Finance Flexibility, REMS, And Manufacturing Get Attention
User fee reauthorization negotiators from US FDA and industry divide into subgroups to tackle specific issues before moving to the broader agreement.
How US FDA And Industry Are Looking To Navigate New Supply Chain Data Reporting Requirements
FDA Commissioner Hahn says industry needs to work with the agency to establish a link to more detailed supply chain information.